Emmessar Biotech&Nut
Ticker > Company >

Emmessar Biotech&Nut share price

Emmessar Biotech & Nutrition Ltd.

BSE: 524768 SECTOR: Pharmaceuticals & Drugs  12.15 K   53   2

30.52
-1.60 (-4.98%)
BSE: 28 Jul 04:01 PM

Price Summary

Today's High

₹ 33.21

Today's Low

₹ 30.52

52 Week High

₹ 64

52 Week Low

₹ 27.25

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 15.25 Cr.

Enterprise Value

₹ 9.17 Cr.

No. of Shares

0.5 Cr.

P/E

48.1

P/B

1.98

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  15.43

CASH

₹ 6.18 Cr.

DEBT

₹ 0.11 Cr.

Promoter Holding

59.53 %

EPS (TTM)

₹  0.63

Sales Growth

-45.53%

ROE

10.66 %

ROCE

11.42%

Profit Growth

48.79 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-45.53%
3 Year-57.02%
5 Year-2.48%

Profit Growth

1 Year48.79%
3 Year-19.74%
5 Year7.06%

ROE%

1 Year10.66%
3 Year8.84%
5 Year15%

ROCE %

1 Year11.42%
3 Year14.04%
5 Year21.26%

Debt/Equity

0.0148

Price to Cash Flow

23.66

Interest Cover Ratio

626.0769

CFO/PAT (5 Yr. Avg.)

1.2178651129545

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 59.53 0.00
Mar 2025 59.53 0.00
Dec 2024 59.53 0.00
Sep 2024 59.53 0.00
Jun 2024 59.53 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company’s PEG ratio is 0.985871482885315.
  • The company has an efficient Cash Conversion Cycle of 68.1804 days.
  • Company has a healthy liquidity position with current ratio of 12.9479.
  • The company has a good cash flow management; CFO/PAT stands at 1.2178651129545.
  • The company has a high promoter holding of 59.53%.

 Limitations

  • The company has shown a poor profit growth of -19.7374631291371% for the Past 3 years.
  • The company has shown a poor revenue growth of -57.015508234658% for the Past 3 years.
  • The company has a low EBITDA margin of -101.387845775802% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 0.08 0.08 0.34 0.1 0.1
Total Expenditure 0.47 0.35 0.42 0.38 0.42
Operating Profit -0.39 -0.27 -0.08 -0.28 -0.32
Other Income 0.48 0.46 0.51 0.43 0.61
Interest 0 0 0 0 0
Depreciation 0.02 0.02 0.02 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.07 0.16 0.41 0.13 0.26
Tax -0.2 0.07 0.13 0.11 0.33
Profit After Tax 0.27 0.09 0.28 0.02 -0.07
Adjusted EPS (Rs) 0.54 0.18 0.56 0.04 -0.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 3.4 6.99 0.36 1.02 0.56
Total Expenditure 3.8 6.14 1.26 1.71 1.64
Operating Profit -0.4 0.85 -0.89 -0.69 -1.08
Other Income 1.47 1.47 1.92 1.75 1.99
Interest 0 0 0 0 0
Depreciation 0.06 0.06 0.09 0.09 0.1
Exceptional Items -0.26 0 0 0 0
Profit Before Tax 0.74 2.25 0.93 0.97 0.81
Tax -0.02 0.8 0.46 0.46 0.06
Net Profit 0.75 1.45 0.48 0.5 0.75
Adjusted EPS (Rs.) 1.51 2.9 0.95 1.01 1.5

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 5 5 5 5 5
Total Reserves -0.73 0.7 1.17 1.67 2.41
Borrowings 0 0 0 0 0
Other N/C liabilities -0.17 0.16 0.44 0.86 0.84
Current liabilities 1.32 1.63 0.99 0.57 0.53
Total Liabilities 5.41 7.49 7.6 8.09 8.77
Assets
Net Block 1.91 1.86 1.46 1.4 1.31
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.01 0.01 0 0 0
Other N/C Assets 0 0 0.62 0.61 0.6
Current Assets 3.49 5.62 5.52 6.08 6.86
Total Assets 5.41 7.49 7.6 8.09 8.77
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1 2.25 0.93 0.97 0.81
Adjustment -0.31 -0.07 -0.13 -0.15 -0.42
Changes in Assets & Liabilities 0.34 -1.61 1.76 -0.5 0.24
Tax Paid 0 -0.1 -0.29 0.06 0.02
Operating Cash Flow 1.03 0.47 2.27 0.38 0.64
Investing Cash Flow -1.06 0.01 -2.61 -0.55 -0.64
Financing Cash Flow 0 0 0 0 0
Net Cash Flow -0.03 0.48 -0.34 -0.17 0

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 59.53 59.53 59.53 59.53 59.53
aman manoj shah 0.33 0.33 0.33 0.33 0.33
amu investment & finance ... 5.20 5.20 5.20 5.20 5.20
amu shares & securities l... - - - 0.01 0.01
appaji venkata krishna mo... 0.10 0.10 0.10 0.10 0.10
arvind moolchand shah 1.33 1.33 1.33 1.33 1.33
arvind moolchand shah (hu... 1.13 1.13 1.13 1.13 1.13
bhavik arvind shah 0.91 0.91 0.91 0.91 0.91
emmessar technologies lim... 21.79 21.79 21.79 21.79 21.79
hema a shah 5.37 5.37 5.37 5.37 5.37
jyothi satyanarayana mall... 0.76 0.76 0.76 0.76 0.76
m s raghavan 5.68 5.68 5.68 5.68 5.68
manar leasing & investmen... 10.57 10.57 10.57 10.57 10.57
prabha vijaykumar agarwal... 0.29 0.29 0.29 0.29 0.29
rajalakshmi raghavan 3.41 3.41 3.41 3.41 3.41
sarada srinivasa raghavan... 0.52 0.52 0.52 0.52 0.52
satyanarayana malla 0.37 0.37 0.37 0.37 0.37
vasudevan raghavan 0.07 0.07 0.07 0.07 0.07
vijay kumar makarla 0.10 0.10 0.10 0.10 0.10
vijaykumar raghunandanpra... 1.59 1.59 1.59 1.59 1.59
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 40.47 40.47 40.47 40.47 40.47
sandeep rao 1.78 - 1.99 2.04 2.04
llp - - - 0.15 -
sandeep rao - 1.92 - - -

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Emmessar Biotech&Nut Stock Price Analysis and Quick Research Report. Is Emmessar Biotech&Nut an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Emmessar Biotech&Nut and its performance over the period of time. Emmessar Biotech&Nut stock price today is Rs 30.52.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Emmessar Biotech&Nut cash from the operating activity was Rs 0.6446 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Emmessar Biotech&Nut has a Debt to Equity ratio of 0.0148 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Emmessar Biotech&Nut , the EPS growth was 48.7902 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Emmessar Biotech&Nut has OPM of -194.632564841499 % which is a bad sign for profitability.
     
  • ROE: Emmessar Biotech&Nut have a average ROE of 10.6576 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Emmessar Biotech&Nut is Rs 30.52. One can use valuation calculators of ticker to know if Emmessar Biotech&Nut share price is undervalued or overvalued.
Last Updated on:
Brief about Emmessar Biotech&Nut
X